Clinical Trial of Viaskin

May 12, 2023

A recent clinical trial of visaskin patch has demonstrated promising results in preventing severe allergic reactions in toddlers with peanut allergies.

The Clinical Trial

More than 200 children between the ages of 1 to 3, all with peanut allergies, participated in the late-stage clinical trial. The primary objective was to assess the effectiveness of the Viaskin patch in mitigating severe allergic reactions. The findings of the trial were published in the prestigious New England Journal of Medicine.

Results and Benefits

After wearing the Viaskin patch for approximately 22 hours a day over the course of a year, an astounding 67% of the children were able to tolerate a significant amount of peanut protein. This tolerance ranged from 300 to 1,000 milligrams, equivalent to one to four peanuts. Notably, the trial revealed a decrease in the number of severe reactions among the participants.

Understanding the Viaskin Patch

The Viaskin patch, worn between the shoulder blades, delivers a small dose of peanut protein to the wearer’s skin. The immune cells then transport this protein throughout the body, suppressing the allergic response. This innovative approach aims to create a protective layer, reducing the risk of severe reactions even in the event of accidental peanut exposure.

Addressing a Growing Concern

Peanut allergies affect approximately 1 in 50 children in the United States, and the prevalence of this condition has tripled over the past two decades. With no approved treatments for children under 4 years old, the Viaskin patch offers a glimmer of hope in addressing this pressing concern.

Comparing Interventions

While the Viaskin patch trial focused on wearable technology, other interventions are also being researched. For instance, a recent Phase 2 trial explored the use of a minute amount of peanut protein administered under the tongue. These innovative approaches aim to increase tolerance to peanuts over time, providing potential alternatives for those with peanut allergies.

Future Plans

DBV Technologies has expressed its intention to submit Viaskin to the Food and Drug Administration (FDA) for approval. The company acknowledges the need for further safety data, particularly in toddlers and children, before making the application. Although no specific timeline has been provided, the potential approval of the Viaskin patch brings hope to parents and caregivers of children with peanut allergies

« Previous Post Next Post »